Paion happy with CeNeS's morphine-6-glucuronide
This article was originally published in Scrip
Executive Summary
German biotech company Paion has declared itself satisfied with a meta-analysis of Phase II and III data involving the potential intravenous analgesic product, morphine-6-glucuronide (M6G), which it acquired when it bought the UK firm, CeNeS Pharmaceuticals, in June.